Paper Details

  1. Home
  2. Paper Details

Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.

Author: AnuragMeenakshi, ChenChing Hui, DobroleckiLacey E, EllisMatthew J, GutierrezCarolina, KalraRashi, KaranamBalasubramanyam, KavuriShyam M, LewisAlaina, LimBora, SalamAhmad Bin, SallasChristina, WangJunkai, YatesClayton C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Neratinib, a pan-HER tyrosine kinase inhibitor, is effective against metastatic breast cancers with HER2 mutations, but responses are variable and often not durable. This study reveals that recurrent HER2 mutations impact endocrine therapy responsiveness, metastasis, and sensitivity to pan-HER TKIs. The study shows that poziotinib, a pan-HER TKI, is more effective than neratinib in treating HER2 mutant metastatic breast cancer, supporting the need for clinical evaluation of poziotinib for this indication.
Paper Details　
Original Abstract of the Article :
The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations have differential effects on endocrine therapy re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379360/

データ提供：米国国立医学図書館（NLM）

Poziotinib: A Potential Oasis in the Desert of HER2-Mutant Breast Cancer

Breast cancer, a relentless adversary, can be particularly challenging when it harbors activating HER2 mutations. This study, published in the journal *[Journal Name]*, investigates the potential of poziotinib, a pan-HER tyrosine kinase inhibitor (TKI), as a treatment option for HER2-mutant metastatic breast cancer. The study explores the efficacy of poziotinib in overcoming therapeutic resistance and inhibiting multiorgan metastasis, a formidable obstacle in the fight against HER2-mutant breast cancer.

Poziotinib: A Promising Weapon Against HER2-Mutant Resistance

The study demonstrated that poziotinib, unlike other pan-HER TKIs, effectively inhibited tumor growth, reduced multiorgan metastasis, and inhibited mTOR activation, highlighting its potential to overcome therapeutic resistance and address a crucial aspect of HER2-mutant breast cancer management. The study also found that poziotinib showed therapeutic effects in both engineered and patient-derived xenograft models, suggesting its potential for clinical application.

Hope for a More Effective Treatment

This research offers a glimmer of hope for patients battling HER2-mutant metastatic breast cancer. The study's findings provide compelling evidence for the potential of poziotinib to effectively combat this challenging form of cancer, offering a beacon of hope in the fight against this disease. The study also emphasizes the need for further clinical evaluation to confirm the efficacy and safety of poziotinib in treating HER2-mutant breast cancer.

Dr. Camel's Conclusion

The desert of HER2-mutant breast cancer can be a daunting landscape. This study highlights the potential of poziotinib to provide a much-needed oasis, offering hope for more effective treatment strategies. The findings underscore the importance of ongoing research and clinical trials to develop novel therapies for this challenging form of cancer.

Date :
  1. Date Completed 2022-08-17
  2. Date Revised 2023-01-06
Further Info :

Pubmed ID

35736563

DOI: Digital Object Identifier

PMC9379360

Related Literature

Article Analysis
・Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.